4.8 Article

Treatment of Higher-Risk Patients With an Indication for Revascularization Evolution Within the Field of Contemporary Percutaneous Coronary Intervention

Journal

CIRCULATION
Volume 134, Issue 5, Pages 422-+

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.116.022061

Keywords

angioplasty; coronary artery disease; coronary occlusion; heart failure; percutaneous coronary intervention

Funding

  1. Boston Scientific
  2. Medtronic
  3. Abbott Vascular
  4. Abiomed
  5. St. Jude Medical
  6. Eli Lilly
  7. Abiomed Inc.
  8. Daiichi Sankyo
  9. Gilead Sciences
  10. Daiichi-Sankyo/Eli Lilly and Co
  11. AstraZeneca
  12. Boehringer Ingelheim
  13. Bristol-Myers Squibb
  14. Janssen Pharmaceuticals
  15. Liposcience
  16. Medicines Company
  17. Merck/Schering Plow
  18. Pozen
  19. Roche
  20. Sanofi-Aventis
  21. WebMD
  22. Thoratec
  23. Heartware
  24. Cardiac Assist
  25. Maquet
  26. Bristol-Myers Squibb/Sanofi
  27. Eli Lilly and Co/Daiichi-Sankyo
  28. Covidien
  29. Regado Biosciences
  30. Maya Medical
  31. Merck Co

Ask authors/readers for more resources

Patients with severe coronary artery disease with a clinical indication for revascularization but who are at high procedural risk because of patient comorbidities, complexity of coronary anatomy, and/or poor hemodynamics represent an understudied and potentially underserved patient population. Through advances in percutaneous interventional techniques and technologies and improvements in patient selection, current percutaneous coronary intervention may allow appropriate patients to benefit safely from revascularization procedures that might not have been offered in the past. The burgeoning interest in these procedures in some respects reflects an evolutionary step within the field of percutaneous coronary intervention. However, because of the clinical complexity of many of these patients and procedures, it is critical to develop dedicated specialists within interventional cardiology who are trained with the cognitive and technical skills to select these patients appropriately and to perform these procedures safely. Preprocedural issues such as multidisciplinary risk and treatment assessments are highly relevant to the successful treatment of these patients, and knowledge gaps and future directions to improve outcomes in this emerging area are discussed. Ultimately, an evolution of contemporary interventional cardiology is necessary to treat the increasingly higher-risk patients with whom we are confronted.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available